无创肿瘤分子分型:定量增强MRI标志物可预测肝细胞癌的PD-L1与CTNNB1状态
该单中心回顾性研究纳入75例未治疗肝细胞癌患者,基于常规多参数增强MRI提取定量与定性影像标志物,用逻辑回归预测p53失活、CTNNB1激活和PD-L1表达等分子表型;定量影像模型对PD-L1、p53、CTNNB1的AUC分别为0.85、0.79、0.70,临床与定性影像模型AUC较低。
要点
- 定量MRI模型预测PD-L1的AUC为0.85(95%CI 0.74–0.96)。
- p53模型用临床数据AUC 0.36(P<.001)、定性影像AUC 0.41(P=.003),均低于定量影像的0.79。
- 定量MRI标志物来自全肿瘤与肝体积分割,或可无创预测p53、PD-L1、CTNNB1状态。
核心结论
- 源自全肿瘤与肝体积的定量MRI标志物可能预测肝细胞癌的p53、PD-L1和CTNNB1状态。
研究设计与样本
- 单中心回顾性研究,纳入2006年9月至2022年2月间接受肿瘤切除或肝移植的未治疗肝细胞癌患者75例(平均年龄65.7岁±9.43[SD],男性60例),获取多参数增强MRI数据,从病灶与肝段分割中提取定量和定性影像标志物,以切除标本免疫组化结果为参考标准,对每个分子表型分别建立基于定量影像、定性影像或临床数据的多变量逻辑回归模型,用AUC评价并作DeLong检验比较。
诊断标准与关键数值
- 定量影像模型预测PD-L1的AUC为0.85(95%CI 0.74–0.96)、p53为0.79(95%CI 0.66–0.93)、CTNNB1为0.7(95%CI 0.46–0.93);p53的临床数据模型AUC为0.36(95%CI 0.2–0.53,P<.001),定性影像模型AUC为0.41(95%CI 0.21–0.62,P=.003)。
临床应用与阅片要点
- 作者认为定量MRI标志物可能预测肝细胞癌的p53、PD-L1和CTNNB1状态,从而有望辅助生物标志物指导的治疗分配。
局限性
- 单中心回顾性研究,样本量为75例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Systemic molecular-targeted therapy is the standard of care for patients presenting with advanced-stage hepatocellular carcinoma (HCC); however, tumor response rates are limited, mainly owing to HCC biomolecular and pathologic heterogeneity. Therefore, novel markers for noninvasive molecular profiling are needed.
PURPOSE: To determine whether advanced image analysis and machine learning on routinely acquired MRI scans can help predict HCC molecular profiles, thereby allowing biomarker-guided treatment allocations.
MATERIALS AND METHODS: This single-center retrospective study included treatment-naive patients with HCC who underwent tumor resection or liver transplant between September 2006 and February 2022. Multiparametric contrast-enhanced MRI data were obtained, and quantitative and qualitative imaging markers were extracted from lesion and liver segmentations. Pathologic analysis of the resected samples was performed via immunohistochemistry to assess p53 loss of function; catenin beta 1 (CTNNB1) activation; forkhead box M1 activation; and programmed cell death ligand 1 (PD-L1), phosphorylated AKT serine/threonine kinase, phosphorylated SMAD2/3, and sterol O-acyltransferase 1 expression. For each molecular profile outcome, a multivariable logistic regression model was built separately using quantitative imaging, qualitative imaging, or clinical data. The area under the receiver operating characteristic curve (AUC) was used to evaluate model discriminatory performance, and DeLong tests were performed to compare AUCs across models trained on the different data.
RESULTS: Seventy-five patients with T1-weighted, contrast-enhanced, dynamic MRI scans (mean age, 65.7 years ± 9.43 [SD]; 60 males) were included. Receiver operating characteristic curve analysis demonstrated the good discriminatory performance of logistic regression models trained on quantitative imaging data for PD-L1, p53, and CTNNB1, with AUCs of 0.85 (95% CI: 0.74, 0.96), 0.79 (95% CI: 0.66, 0.93), and 0.7 (95% CI: 0.46, 0.93), respectively. Models trained on clinical and qualitative imaging data yielded lower AUCs across profiles, of 0.36 (95% CI: 0.2, 0.53; P < .001) and 0.41 (95% CI: 0.21, 0.62; P = .003), respectively, for p53.
CONCLUSION: Quantitative MRI markers derived from whole tumor and liver volumes can potentially predict p53, PD-L1, and CTNNB1 status in HCC. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Cannella in this issue.
引用
- Matuschewski NJ, Sobirey R, Revzin M, et al. Noninvasive Tumor Profiling: Quantitative Contrast-Enhanced MRI Markers Predict PD-L1 and CTNNB1 Status in Hepatocellular Carcinoma. Radiology. 2025. PMID: 40762840. doi:10.1148/radiol.242750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。